Joanna Zawitkowska1, Monika Lejman2, Agnieszka Zaucha-Prażmo3, Katarzyna Drabko3, Marcin Płonowski4, Joanna Bulsa5, Michał Romiszewski6, Agnieszka Mizia-Malarz7, Andrzej Kołtan8, Katarzyna Derwich9, Grażyna Karolczyk10, Tomarz Ociepa11, Magdalena Ćwiklińska12, Joanna Trelińska13, Joanna Owoc-Lempach14, Maciej Niedźwiecki15, Aleksandra Kiermasz16, Jerzy Kowalczyk3. 1. Department of Pediatric Hematology, Oncology and Transplantology, Medical University of Lublin, Lublin, Poland jzawitkowska1971@gmail.com. 2. Department of Pediatric Hematology, Oncology and Transplantology, University Children's Hospital, Genetic Diagnostic Laboratory, Lublin, Poland. 3. Department of Pediatric Hematology, Oncology and Transplantology, Medical University of Lublin, Lublin, Poland. 4. Department of Pediatric Oncology, Hematology, Medical University of Białystok, Białystok, Poland. 5. Department of Pediatrics, Hematology and Oncology, Medical University of Zabrze, Zabrze, Poland. 6. Department of Hematology and Pediatrics, Children's Hospital, Warsaw, Poland. 7. Department of Pediatric Oncology, Hematology and Chemotherapy, Medical University of Katowice, Katowice, Poland. 8. Department of Pediatrics, Hematology and Oncology, Collegium Medicum of Bydgoszcz, Bydgoszcz, Poland. 9. Department of Pediatric Oncology, Hematology and Transplantology, Medical University of Poznań, Poznań, Poland. 10. Department of Pediatric Oncology and Hematology, Children's Hospital, Kielce, Poland. 11. Department of Pediatrics, Hematology and Oncology, Medical University of Szczecin, Szczecin, Poland. 12. Department of Pediatric Oncology and Hematology, Children's University Hospital, Kraków, Poland. 13. Department of Pediatrics, Oncology, Hematology and Diabetology, Medical University of Łódź, Łódź, Poland. 14. Department of Pediatric Transplantology, Oncology, Hematology, Medical University of Wrocław, Wrocław, Poland. 15. Department of Pediatrics, Hematology, Oncology and Endocrinology, Medical University of Gdańsk, Gdańsk, Poland. 16. Department of Pediatric Hematology and Oncology, Centre of Pediatrics and Oncology, Chorzów, Poland.
Abstract
BACKGROUND/AIM: The risk factors, clinical features and non-hematological toxicity profiles during chemotherapy in acute lymphoblastic leukemia (ALL) patients treated in pediatric hematology centres were analysed. MATERIALS AND METHODS: A total of 902/1872 children were reported as having grade 3 or 4 toxicity. RESULTS: Among the analysed toxicities, infection and gastrointestinal and liver toxicities were the most common. The median follow-up was 6.8 years. Overall survival and event-free survival rates for the analysed group were lower than those reported for the group without grade ≥3 toxicity. In univariate analysis, we identified the number of toxic episodes, the risk group and remission status that had a significant impact on the outcome. Multivariate analysis demonstrated the risk group and the number of toxic episodes ≥3 to be statistically significant for the results. CONCLUSION: The toxic profiles investigated in our report should be used in future efforts to decrease the burden of side effects during chemotherapy. Copyright
BACKGROUND/AIM: The risk factors, clinical features and non-hematological toxicity profiles during chemotherapy in acute lymphoblastic leukemia (ALL) patients treated in pediatric hematology centres were analysed. MATERIALS AND METHODS: A total of 902/1872 children were reported as having grade 3 or 4 toxicity. RESULTS: Among the analysed toxicities, infection and gastrointestinal and liver toxicities were the most common. The median follow-up was 6.8 years. Overall survival and event-free survival rates for the analysed group were lower than those reported for the group without grade ≥3 toxicity. In univariate analysis, we identified the number of toxic episodes, the risk group and remission status that had a significant impact on the outcome. Multivariate analysis demonstrated the risk group and the number of toxic episodes ≥3 to be statistically significant for the results. CONCLUSION: The toxic profiles investigated in our report should be used in future efforts to decrease the burden of side effects during chemotherapy. Copyright
Authors: Jan Styczynski; Robert Debski; Krzysztof Czyzewski; Katarzyna Gagola; Ewa Marquardt; Krzysztof Roszkowski; Janusz Winiecki; Ninela Irga-Jaworska; Marcin Hennig; Katarzyna Muszynska-Roslan; Marcin Plonowski; Tomasz Ociepa; Monika Lecka; Joanna Konieczek; Przemyslaw Galazka; Monika Pogorzala; Monika Richert-Przygonska; Mariusz Wysocki Journal: In Vivo Date: 2021 Nov-Dec Impact factor: 2.155